Ray Therapeutics, Inc.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Ray Therapeutics, Inc.
RECRUITINGPhase 1 / Phase 2NCT07439887
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients...
A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in...
Sponsor: Ray Therapeutics, Inc.Enrolling: 182 locations
Stargardt Disease
RECRUITINGNCT06375239
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal...
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...
Sponsor: Ray Therapeutics, Inc.Enrolling: 1201 location
Retinitis PigmentosaChoroideremiaStargardt Macular Dystrophy+4
RECRUITINGNCT07502664
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited...
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The...
Sponsor: Ray Therapeutics, Inc.Enrolling: 251 location
Retinitis PigmentosaStargardt Macular DystrophyStargardt Disease+3